TABLE 1.

Characteristics of trials

	ZUMA‐7	BELINDA	TRANSFORM
	Locke et al. 15 2021	Bishop et al. 16 2021	Kamdar et al. 14 2021
Autologous Anti‐CD19 CAR	Axicabtagene ciloleucel	Tisagenlecleucel	Lisocabtagene maraleucel
Co‐stimulatory domain	CD28	4‐1BB	4‐1BB
T‐cell selection	No	No	CD4:CD8
Inclusion criteria	RD and relapse <1 year	RD and relapse<1 year	RD and relapse <1 year
	LBCL	LBCL PMBL FL3B Hx of CNS	LBCL PMBL FL3B Sec. CNS lymphoma
Randomisation	1:1	1:1	1:1
Randomisation stratification	sAAIPI RD vs. relapsed disease.	sAAIPI RD and relapse <6 months vs. relapse 6–12 months. US vs. non‐US	sAAIPI RD and relapse <3 months vs. relapse 3–12 months.
Primary outcome	EFS	EFS	EFS
Definition of EFS	Time from randomisation to death or PD, or failure to achieve CR or PR by day 150 or start of new anti‐neoplastic therapy.	Time from randomisation to SD or PD at or after the week 12 assessment or death at any time.	Time from randomisation to death or PD or failure to achieve CR or PR by 9 weeks or start of new anti‐neoplastic therapy.
Date of initial response assessment	Day 50 and 100	Weeks 6 and 12	Weeks 9 and 18
CAR‐T therapy arm
Bridging chemotherapy	No (only steroids)	Allowed (switching allowed)	Allowed
Lymphodepletion	Flu 30/Cy500 mg/m2 X3d	Flu 25/Cy250 mg/m2 X3d	Flu 30/Cy300 mg/m2 X3d
Cell dose	2 × 106 cell/kg	0.6‐6 × 108 cells Median 2.9 × 108	1 × 108 cells
SOC arm
Salvage regimen	ICE DHAP GDP ESHAP	ICE DHAP GDP GEMOX	ICE DHAP GDP
Cycle number	2–3	2 (Switching allowed)	3

Abbreviations: DHAP, dexamethasone‐cytarabine‐cisplatin; ESHAP, etoposide‐methylprednisolone‐cytarabine‐cisplatin; FL3B, follicular lymphoma grade 3B; GDP, gemcitabine‐dexamethasone‐cisplatin; GEMOX, gemcitabine‐oxaliplatin; ICE, ifosfamide‐carboplatin‐etoposide; PD, progressive disease; PMBL, primary mediastinal B cell lymphoma; RD, refractory disease; sAAIPI, second‐line age‐adjusted International Prognostic Index; US, United States.